Canaccord Genuity Reiterates Buy on Madrigal Pharmaceuticals, Maintains $336 Price Target
Portfolio Pulse from richadhand@benzinga.com
Canaccord Genuity analyst Edward Nash has reiterated a 'Buy' rating on Madrigal Pharmaceuticals (NASDAQ:MDGL) and maintained a price target of $336.
July 18, 2023 | 1:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity has reiterated a 'Buy' rating on Madrigal Pharmaceuticals and maintained a price target of $336.
The reiteration of a 'Buy' rating by Canaccord Genuity, a reputable financial services firm, is a positive signal for Madrigal Pharmaceuticals. The maintained price target of $336 indicates that the analyst believes the stock has significant upside potential. This could lead to increased investor confidence and potentially a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100